Journal Mobile Options
Table of Contents
Vol. 74, No. 1, 2005
Issue release date: December 2004

The Use of Placebo in Clinical Trials on Bipolar Disorder: A New Approach for an Old Debate

Vieta E. · Carné X.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Placebo response is high in bipolar disorder trials. This is a challenge for researchers and an enigma for clinicians. This article will attempt to aid in the comprehension of the ethical questions and methodologies related to the use of placebo in bipolar disorder. Methods: A systematic review of the main computerized data bases (Medline, Embase, Psychlit, Current Contents) was carried out, using the following key words: placebo, bipolar disorder, mania, depression, clinical trial. Results: Placebo has a very important role in the study of bipolar disorders. From a methodological point of view, and given the limitations of non-inferiority designs, the use of placebo is necessary to evaluate the sensitivity of the study and ensure that the drug under investigation is really effective. For this reason, several procedures may be used to satisfactorily solve the ethical objections. Placebo response in bipolar disorder trials is more likely to occur in patients who are mildly ill, bipolar II, mixed-episode, first-episode, rapid cycling, atypical, non-psychotic, substance abusers and medically ill. The use of concomitant medication such as benzodiazepines, a high frequency of visits, a high number of treatment groups and sites, fixed-dose designs, and the concomitant use of psychotherapy are likely to increase placebo response. Conclusion: The subject of the use of placebo in psychiatric clinical trials leads to very relevant ethical, methodological and clinical dilemmas. Many reasons support the use of placebo in acute bipolar studies, whereas in maintenance the length of the treatment with placebo makes the decision more difficult. Ethical concerns can be addressed through operational definitions of outcome measures, add-on and discontinuation designs, early escape strategies, and processes designed to make sure that fully informed consent was fairly obtained. There are a number of clinical and methodological variables that are associated with placebo response.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Keck PE Jr, Welge JA, Strawoski SM, Arnold LM, McElroy SL: Placebo effect in randomized, controlled maintenance studies of patients with bipolar disorder. Biol Psychiatry 2000;47:756–761.
  2. Charney DS, Nemeroff CB, Lewis L, Laden SK, Gorman JM, Laska EM, Borenstein M, Bowden CL, Caplan A, Emslie GJ, Evans DL, Geller B, Grabowski LE, Herson J, Kalin NH, Keck PE Jr, Kirsch I, Krishnan KR, Kupfer DJ, Makuch RW, Miller FG, Pardes H, Post R, Reynolds MM, Roberts L, Rosenbaum JF, Rosenstein DL, Rubinow DR, Rush AJ, Ryan ND, Sachs GS, Schatzberg AF, Solomon S; Consensus Development Panel: National Depressive and Manic-Depressive Association Consensus Statement on the use of placebo in clinical trials of mood disorders. Arch Gen Psychiatry 2002;59:262–270.
  3. Post RM, Denicoff KD, Leverich GS: Special issues in trial design and use of placebo in bipolar illness. Biol Psychiatry 2000;47:727–732.
  4. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG Jr, Choce JCY, Keeck PE Jr, Rhodes LJ, Swann AC, Hirschfeld RMA, Wozwak PG, for the Divalproex Maintenance Study Group: A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000;57:481–489.
  5. Temple R, Ellenberg SS: Placebo-controlled trials and active-control trials in the evaluation of new treatments. 1. Ethical and scientific issues. Ann Intern Med 2000;133:455–463.
  6. Baldessarini R, Tohen M, Tondo L: Maintenance treatment in bipolar disorder. Arch Gen Psychiatry 2000;57:490–491.
  7. Khan A, Warner HA, Brown WA: Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials; an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 2000;57:311–317.
  8. Vestergaard P: How effective is long-term lithium prophylaxis. Acta Psychiatr Scand 2000;101:341–342.
  9. Johnson RE, McFarland BH: Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry 1996;153:993–1000.
  10. Fleischhacker WF: Placebo or active control trials of antipsychotic drugs? Arch Gen Psychiatry 2003;60:458–464.
  11. Vieta E, Torrent C: Atypical antipsychotic drugs in the acute and maintenance treatment of bipolar disorder; in Vieta E (ed): Bipolar Disorders: Clinical and Therapeutic Progress. Madrid, Panamericana, 2001, pp 159–167.
  12. Suppes T, Baldessarini RJ, Faedda GL, Tohen M: Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991;48;1082–1088.
  13. Tondo L, Baldessarini RJ: Reduced suicide risk during lithium maintenance treatment. J Clin Psychiatry 2000;61(suppl 9):97–104.

    External Resources

  14. Consensus Meeting: ECNP Consensus Meeting March 2000 Nice Guidelines for investigating efficacy in Bipolar Disorder. Eur Neuropsychopharmacol 2001;11:79–88.
  15. Bowden Cl, Swann AC, Calabrese JR, McElroy SL, Morris D, Petty F, Hirschfeld RM, Gyulai L: Maintenance clinical trials in bipolar disorder: Design implications of the divalproex-lithium-placebo study. Psychopharmacol Bull 1997;33:693–699.

    External Resources

  16. Zimmerman M, Posternak M: Placebo response in antidepressant efficacy trials: Relationship to number of active treatment groups. 156th Annu Meet Am Psychiatr Assoc, San Francisco, May 17–22, 2003.
  17. Khan A, Khan S: Placebo in mood disorders: The tail that wags the dog. Curr Opin Psychiatry 2003;16:35–39.

    External Resources

  18. Mayberg HS, Silva JA, Brannan SK, Tekell JL, Mahurin RK, McGinnis S, Jerabek PA: The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002;159:728–737.
  19. Fava M, Evins AE, Dorer DJ, Schoenfeld DA: The problem of the placebo response in clinical trials for psychiatric disorders: Culprits, possible remedies, and a novel study design approach. Psychother Psychosom 2003;72:115–127.
  20. Tohen M, Sanger TM, Tollefson GD, et al: Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH study group. Am J Psychiatry 1999;156:702–709.
  21. Vieta E: Do we need placebo control in maintenance studies in bipolar disorders? Bipolar Disord 2002;4(suppl 1):61.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50